Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

Thumbnail for Gender-based Differences in Presentation and Outcomes of Mantle Cell Lymphoma: A 25-Year Institutional Experience

MCL - 577

Gender-based Differences in Presentation and Outcomes of Mantle Cell Lymphoma: A 25-Year Institutional Experience

Pallawi Torka

Poster Presenter: Pallawi Torka

Thumbnail for Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial

MM - 578

Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial

Abdullah Khan

Poster Presenter: Abdullah Khan

Thumbnail for Ionized Calcium Outperforms Corrected Calcium for Hypercalcemia Assessment in Multiple Myeloma

MM - 579

Ionized Calcium Outperforms Corrected Calcium for Hypercalcemia Assessment in Multiple Myeloma

Mario Alberto Ochoa Rodriguez

Poster Presenter: Mario Alberto Ochoa Rodriguez

Thumbnail for Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

CLL - 580

Impact of Type 2 Diabetes on Cardiovascular Toxicity, Infectious Complications, and Survival Among Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Propensity-Matched TriNetX Analysis

Jude Ossai

Poster Presenter: Jude Ossai

Thumbnail for Frontline ABVD Chemotherapy Outcomes in Hodgkin Lymphoma in a Resource-Limited Setting: Real-World Survival and Prognostic Factors

HL - 582

Frontline ABVD Chemotherapy Outcomes in Hodgkin Lymphoma in a Resource-Limited Setting: Real-World Survival and Prognostic Factors

Hammad Javed

Poster Presenter: Hammad Javed

Thumbnail for ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome

MDS - 583

ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome

Shuyan Huang

Poster Presenter: Shuyan Huang

Thumbnail for The Prognostic Value of Day 14 Bone Marrow Blast Clearance Is Mutation-Dependent in Newly Diagnosed, Intensively Treated Acute Myeloid Leukemia (AML)

AML - 585

The Prognostic Value of Day 14 Bone Marrow Blast Clearance Is Mutation-Dependent in Newly Diagnosed, Intensively Treated Acute Myeloid Leukemia (AML)

Zuzanna Nowicka-Kaszkowiak

Poster Presenter: Zuzanna Nowicka-Kaszkowiak

Thumbnail for Mutational Landscape and Hematological Correlations in Myeloproliferative Neoplasms: A 5-Year Retrospective Study from a Lebanese Tertiary Center

MPN - 586

Mutational Landscape and Hematological Correlations in Myeloproliferative Neoplasms: A 5-Year Retrospective Study from a Lebanese Tertiary Center

Sarah Gerges

Poster Presenter: Sarah Gerges

Thumbnail for Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Adults With Immune Thrombocytopenia: A Systematic Review and Single-Arm Meta-Analysis

CT - 587

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Adults With Immune Thrombocytopenia: A Systematic Review and Single-Arm Meta-Analysis

Gamaliel Monge-Ruiz

Poster Presenter: Gamaliel Monge-Ruiz

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.